Brokerages Set American Renal Associates Holdings Inc (ARA) Target Price at $18.67

Shares of American Renal Associates Holdings Inc (NYSE:ARA) have been assigned a consensus rating of “Hold” from the nine brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is $17.86.

ARA has been the subject of a number of recent research reports. ValuEngine downgraded shares of American Renal Associates from a “hold” rating to a “sell” rating in a report on Monday, January 7th. Zacks Investment Research upgraded shares of American Renal Associates from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Monday, February 4th. Barclays initiated coverage on shares of American Renal Associates in a report on Friday, December 14th. They set an “equal weight” rating and a $18.00 price target for the company. Deutsche Bank initiated coverage on shares of American Renal Associates in a report on Thursday, January 3rd. They set a “hold” rating and a $12.00 price target for the company. Finally, Morgan Stanley initiated coverage on shares of American Renal Associates in a report on Friday, December 14th. They set an “equal weight” rating for the company.

Institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers grew its holdings in American Renal Associates by 47.5% in the fourth quarter. Rhumbline Advisers now owns 17,225 shares of the company’s stock valued at $198,000 after purchasing an additional 5,549 shares during the period. MetLife Investment Advisors LLC purchased a new stake in American Renal Associates in the third quarter valued at approximately $230,000. Macquarie Group Ltd. grew its holdings in American Renal Associates by 1,867.7% in the second quarter. Macquarie Group Ltd. now owns 20,700 shares of the company’s stock valued at $326,000 after purchasing an additional 19,648 shares during the period. Russell Investments Group Ltd. purchased a new stake in American Renal Associates in the second quarter valued at approximately $405,000. Finally, Engineers Gate Manager LP grew its holdings in American Renal Associates by 74.4% in the third quarter. Engineers Gate Manager LP now owns 22,892 shares of the company’s stock valued at $496,000 after purchasing an additional 9,764 shares during the period. Hedge funds and other institutional investors own 94.42% of the company’s stock.

Shares of NYSE ARA traded up $0.01 during midday trading on Monday, reaching $11.79. 72,800 shares of the stock were exchanged, compared to its average volume of 96,068. The company has a market cap of $383.05 million, a PE ratio of 19.33, a price-to-earnings-growth ratio of 3.19 and a beta of 2.13. American Renal Associates has a 52-week low of $11.09 and a 52-week high of $24.07. The company has a debt-to-equity ratio of 5.48, a current ratio of 1.03 and a quick ratio of 1.00.

American Renal Associates (NYSE:ARA) last issued its quarterly earnings results on Thursday, November 8th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. The business had revenue of $211.02 million during the quarter, compared to the consensus estimate of $217.15 million. American Renal Associates had a negative net margin of 1.81% and a positive return on equity of 22.30%. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.19 earnings per share. On average, analysts anticipate that American Renal Associates will post 0.61 EPS for the current year.

American Renal Associates Company Profile

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

Read More: How to invest in a bear market

Analyst Recommendations for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply